Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
Nasdaq13d
FDA Approves ONAPGO Apomorphine Hydrochloride For Parkinson's Disease Treatment
(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations ...
HealthDay on MSN4d
FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
Nasdaq13d
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, the First Subcutaneous Apomorphine Infusion Device for Parkinson's Disease in the U.S.
Supernus Pharmaceuticals has announced the FDA approval of ONAPGO, the first subcutaneous apomorphine infusion device specifically designed to treat motor fluctuations in adults with advanced ...
Yahoo Finance12d
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
“Continuous subcutaneous apomorphine infusion already has a proven and established 30-year history in Europe, where it has helped deliver more consistent control of motor fluctuations for ...